Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03455309 · ClinicalTrials.gov registry record · Phase 2
Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
A Phase 2 study, sponsored by NovaDigm Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 382
- Enrollment target
NCT03455309 is a Phase 2 study that has completed, run by NovaDigm Therapeutics. The registered enrollment target is 382 participants.
The verdict
NCT03455309, a Phase 2 study, has completed, sponsored by NovaDigm Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 382 participants
- Enrollment target
Study Summary
The proposed study aims to further evaluate the safety and immunogenicity of a candidate S. aureus vaccine NDV-3A, as well as its efficacy against acquisition of S. aureus
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL NDV-3A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03455309
The ClinicalTrials.gov registry entry for NCT03455309 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovaDigm Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03455309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03455309 about?
NCT03455309 is a clinical study titled "Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization". The proposed study aims to further evaluate the safety and immunogenicity of a candidate S. aureus vaccine NDV-3A, as well as its efficacy against acquisition of S. aureus
What is the current status of trial NCT03455309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 382 participants. The study started on 2018-01-30. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT03455309?
The interventions under investigation include: Placebo (BIOLOGICAL), NDV-3A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03455309?
This trial is sponsored by NovaDigm Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.